NMT Pharma of Singapore In-licenses Cancer Drug from US's CAO Pharma

Singapore's NMT Pharma in-licensed worldwide rights to a cancer drug co-developed by CAO Pharma of Houston, Texas and NMT. CAO developed CZ-48, an analogue of camptothecin, to become active only within tumors. A well-known cytotoxic agent, camptothecin is used in traditional Chinese medicine and is derived from the bark of the camptotheca tree. Other variants of the drug are the approved drugs topotecan and irinotecan. NMT is a CRO with technology that improves the bioavailability of drug candidates. Financial details were not disclosed. More details.... Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.